Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tissue Distribution of PF-06427878 in Healthy Men
NCT02410525Phase 1Completed
- Sponsor
- Pfizer
- Start
- May 2015
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PF-06427878 in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Pfizer. Primary endpoints: Percent injected radioactivity (per gram) over time in the liver and Percent injected radioactivity (per gram) over time in the plasma. Started May 2015; status: completed.
02
Drugs
PF-06427878
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02410525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02410525.